CD38 and neoplasm: Anti-CD38 MoAbs exert their anti-tumor action through multiple mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), direct cellular apoptosis, complement-dependent cytotoxicity (CDC), and the modulation of extracellular ectoenzyme activity (Figure 1) [9].